. There were satisfactory C max and C min only in Patient 2, whereas in Patient 1 there was an increased CL and reduced AUC. Since the PK/pharmacodynamic parameter of importance for linezolid activity is the AUC/MIC ratio, assessing changes in AUC exposure by body size is of paramount importance. 6 Only Patient 2 had satisfactory values of AUC and AUC/MIC.
However, the long-term toxicity of these agents in ageing patients with comorbidities can be a limiting factor in treatment. 2 The clinical evaluation of NRTI-, NNRTI-and PI-sparing strategies is needed.
In light of the respective antiretroviral activities, pharmacokinetic profiles and metabolic characteristics of maraviroc and raltegravir, 3, 4 the trial 'Raltegravir plus Maraviroc Therapy in Controlled HIV Patients Presenting with Lipohypertrophy' (ROCnRAL ANRS 157; NCT01420523) proposed a dual regimen in patients with long-term virological suppression, clinical lipohypertrophy and R5-tropic B or CRF02_AG HIV-1 subtype infection (determined by Sanger DNA sequencing). The study protocol was reviewed and approved by the respective institutional ethics committees. The main objective of this non-comparative, Phase II, multicentre pilot trial was to assess the ability to maintain plasma HIV-1 RNA ,50 copies/mL after 24 weeks of maraviroc plus raltegravir (300/400 mg twice daily). However, this study was prematurely discontinued because of the high treatment failure rate: 7 for the first 44 enrolled of 90 planned patients (5 virological failures and 2 serious adverse events). 5 One of the mechanistic hypotheses for the unexplained virological failures was a deleterious drug interaction between maraviroc and raltegravir or lack of virological robustness of the dual regimen.
This pharmacokinetic substudy aimed to (i) answer the question of drug interaction and (ii) assess free and total plasma concentrations of maraviroc and raltegravir during follow-up and at the time of virological failure.
Eligibility criteria were as for the ROCnRAL trial. 5 Comedications that might affect the respective pharmacokinetics were not allowed. Blood samples were collected at a mean of 12+2 h after the last drug intake for assessing free and total trough plasma concentration (C min ) at weeks 4, 24 and 48 and, if possible, at the time of virological failure. Plasma protein binding analysis involved an ultrafiltration assay with duplicate ultrafiltration (Centrifree, Millipore) (coefficient of variation ,15%). The C min for maraviroc and raltegravir (and its inactive glucuronide metabolite) was determined by LC coupled with tandem MS (Waters Acquity UPLC-TQD; limits of quantification ,1 ng/mL) as described previously, 6 with some modification. The C min for maraviroc and raltegravir were interpreted by the antiviral thresholds of 50 ng/mL. We used a maraviroc threshold of 10 ng/mL that should saturate membrane CCR5 on all CD4 cells 7 and a raltegravir threshold of 15 ng/mL (the IC 95 in 50% human serum). 8 Before the ROCnRAL trial was discontinued, 44 patients (86% male, median age 55 years) were enrolled. In pooled samples collected at weeks 4, 24 and 48, the median (IQR) total C min for maraviroc and raltegravir were 107 ng/mL (54 -165) and 152 ng/mL (95-411), respectively. The free fractions were 42% and 20% for maraviroc and raltegravir, respectively. The C min was .10 ng/mL for most maraviroc free fraction samples (97%; 67/69) and ≥15 ng/mL for 87.5% of raltegravir free fraction samples (63/72) ( Figure 1) . The between-and within-patient variability in total C min was 105% and 35% for maraviroc and 117% and 61% for raltegravir, respectively. The metabolic ratio of glucuronide-raltegravir to raltegravir was 4.1 (2.3-6.4, n¼78) .
This pharmacokinetic study of the ROCnRAL trial confirmed the lack of a clinically relevant drug interaction between maraviroc and raltegravir in a population of mostly male HIV-infected patients with long-term suppressed viraemia and lipohypertrophy. Indeed, neither maraviroc, a CCR5 antagonist, nor raltegravir, an integrase inhibitor, demonstrated similar metabolic pathways. Maraviroc is a substrate of CYP3A4 whereas raltegravir is a substrate of UDP-glucuronyl transferase 1A1 (UGT1A1); both are substrates of P-glycoprotein. 3, 4 Our total C min values for maraviroc and raltegravir are consistent with those for healthy subjects 9 and our free C min values were similar to those previously described (raltegravir, Isentress product information, US FDA). 10 The C min for most maraviroc and raltegravir samples was considered effective considering the respective thresholds of 10 and 15 ng/mL. At each visit, patients were advised to take maraviroc plus raltegravir with food, which probably limited the interpatient variability in C min for both drugs. In this population of HIV-infected patients receiving the maraviroc plus raltegravir dual regimen, without any liver disease or drug interaction via UGT1A1, the C min was 4-fold higher for the glucuronide-raltegravir metabolite than raltegravir.
In conclusion, this pharmacokinetic study of a maraviroc-plusraltegravir dual regimen in HIV patients with long-term virological suppression confirms the lack of deleterious drug interaction between maraviroc and raltegravir. Despite an effective maraviroc and raltegravir C min , the lack of virological robustness should be investigated to detect some minor X4-tropic variants or integrase resistance mutations at baseline or other explanation for the treatment failure with maraviroc plus raltegravir.
